News
NRXP
4.850
+28.99%
1.090
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th
Barchart · 4d ago
NRx Pharmaceuticals' Acquisition Likely to Result in Multiple Avenues of Growth -- Market Talk
Dow Jones · 4d ago
NRx stock rallies 35% on equity purchases, clinic acquisition
Seeking Alpha · 4d ago
NRX Pharmaceuticals Price Target Maintained With a $31.00/Share by D. Boral Capital
Dow Jones · 5d ago
NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital
Dow Jones · 5d ago
*NRX Pharma: Smith & Sauer to Join HOPE Therapeutics, NRx Pharmaceuticals Bds >NRXP
Dow Jones · 5d ago
*NRX Pharma: Investor to Receive Warrants to Buy 3M Currently Unregistered Shrs of NRx Common Stk $3/Shr >NRXP
Dow Jones · 5d ago
*NRX Pharma: Smith & Sauer Entitled to Receive Royalties on Net Rev From NRx Pdt Sales to Defined Rate of Return >NRXP
Dow Jones · 5d ago
*NRX Pharma: Purchase of $2M in NRx Equity, Plus 500,000 NRx Shares From Existing Hldrs, at $2.75/Shr >NRXP
Dow Jones · 5d ago
*NRX Pharma: Purchase of $25M in Series A Preferred Stk in HOPE Convertible Into 1/3 of Fully Diluted HOPE Equity >NRXP
Dow Jones · 5d ago
*NRX Pharm: Cap to Augment Potential Bank Financing for Purchase of HOPE Therapeutics Clinics, Support NRx Pharma Ops >NRXP
Dow Jones · 5d ago
NRx Pharmaceuticals, HOPE sign term sheet for $27M in funding
TipRanks · 5d ago
HOPE Therapeutics And NRx Pharmaceuticals Announce Signing Of Binding Term Sheet For $27M In Funding For HOPE Clinic Acquisitions And Pharmaceutical Operations
Benzinga · 5d ago
NRX PHARMACEUTICALS INC: SMITH & SAUER TO JOIN HOPE THERAPEUTICS AND CO'S BOARDS
Reuters · 5d ago
HOPE THERAPEUTICS™, INC. AND NRX PHARMACEUTICALS, INC. (NASDAQ:NRXP) ANNOUNCE SIGNING OF BINDING TERM SHEET FOR $27 MILLION IN FUNDING FOR HOPE CLINIC ACQUISITIONS AND PHARMACEUTICAL OPERATIONS
Reuters · 5d ago
*HOPE Therapeutics, NRx Pharmaceuticals Sign Binding Term Sheet for $27M in Funding for HOPE Clinic Acquisitions, Pharmaceutical Ops
Dow Jones · 5d ago
Press Release: HOPE Therapeutics(TM), Inc. and -2-
Dow Jones · 5d ago
Press Release: HOPE Therapeutics(TM), Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations
Dow Jones · 5d ago
Best Momentum Stocks to Buy for January 6th
NASDAQ · 5d ago
HOPE Therapeutics announces planned acquisition of Dura Medical
TipRanks · 5d ago
More
Webull provides a variety of real-time NRXP stock news. You can receive the latest news about Nrx Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About NRXP
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.